TrialHeadache2026

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Dale S Bond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.